European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

Table 4 Clinical and hematological findings in thrombocythemia of various myeloproliferative diseases polycythemia vera, primary myelofibrosis and essential thrombocythemia in 395 myeloproliferaive disease patients from the Cologne Institute of Pathology 1980-1989

Diagnosis cologne criteria	PV	PMF	True ET	NV
No. of patients	55	250	40
Thrombocythemia > 500 × 109/L (%)	48	48	100	< 350
Thrombocythemia > 1000 × 109/L (%)	6	17	65
Age (median years)	63	66	58
Male/female	20/35	58/62	14/26
Platelets, × 109/L mean ± SD	808 ± 288	960 ± 361	1386 ± 541	< 350
Erythrocytes, × 10/L mean ± SD	6.7 ± 0.2	4.5 ± 0.1	4.6 ± 0.7	< 6.0
Hemoglobin, g/dL	17.7 ± 0.4	12.8 ± 0.2	13.7 ± 2
Leukocytes	17 ± 1	15 ± 9	13 ± 5
Leukocyte alkaline phosphatase score	164 ± 91	98 ± 83	57 ± 43	< 10
Spleen size increase on palpation (cm)	2.0 ± 3.3	2.6 ± 3.1	0.4 ± 0.8	NP
Observed 10 yr survival (mo)	106	85	170
Specific loss of life expectancy (%)	19	22	3
Bone marrow histopathology	PV	PMF	True ET	RT
Megakaryocytes	Pleomorph	Immature giant	Staghorn	N
Frequency/mm hematopoietic area	123/27	112/37	157/45	98/39
Size (μm2)	385 ± 102	386 ± 197	425 ± 117	328 ± 84
Erythropoiesis × 10	44 ± 8	9 ± 4	22 ± 5	27 ± 4
Granulopoiesis × 10	65 ± 12	58 ± 27	47 ± 15	57 ± 18
Reticulin fibers × 10 (mm )	21 ± 11	97 ± 41	15 ± 7	15 ± 6
No. of patients	120	40
LAP score	110 ± 60	57 ± 43	< 100
Spleen size	1.7 ± 1.4	0.4 ± 0.8	NP
Observed survival (mo)	77	170	-
Specific loss in life expectancy (%)	53	3	0

Data from Thiele et al[90]. MPD: Myeloproliferaive disease; PV: Polycythemia vera; PMF: Primary myelofibrosis; ET: Essential thrombocythemia; LAP: Leukocyte alkaline phosphatase; RT: Reactive thrombocytosis; NV: Normal value; NP: Not palpable; N: Normal.